Three years ago, Eli Lilly heart specialist Jeffrey Riesmeyer scoffed at the notion that the failure of CETP inhibitors at Roche and Pfizer was a bad sign for their big Phase III program for evacetrapib. Evacetrapib wound up proving that Lilly was dead wrong about its theory.
Eli Lilly is shutting down a massive, costly clinical trial after its lead drug came up short in cardiovascular disease, dealing a major blow to the company's pipeline.
Eli Lilly has expanded its R&D partnership with China's Innovent Biologics, bringing in three potential immunotherapies for cancer and adding another $1 billion in potential value to the existing alliance.
Payers may be playing it cool on Jardiance's new cardiovascular edge in the diabetes market, but doctors aren't--and neither are investors. Credit Suisse analyst Vamil Divan tapped physician sentiment in a proprietary survey and concluded that physicians will boost their Jardiance scripts quickly.
China's Innovent Biologics has deepened a pact with Eli Lilly by including immuno-oncology bispecific antibodies for Innovent in Greater China and for the Indianapolis-based firm outside of the country, setting a new benchmark in a white-hot area of collaboration deals.
Eli Lilly is upsizing its New York City R&D outpost, planning to add 50 new jobs and take up more lab space with a particular focus on immuno-oncology.
Eli Lilly's would-be rival to Pfizer's Ibrance (palbociclib) just gained an inside track at the FDA. Regulators handed Lilly the coveted "breakthrough therapy" designation for abemaciclib, another CDK 4/6 inhibitor with big plans for carving out a niche among patients with advanced breast cancer.
Recently, Eli Lilly and Boehringer Ingelheim's Jardiance became the first diabetes drug to show it could reduce the combined risk of heart attack, stroke and death from cardiovascular causes--doing so by 14% in a study of high-risk Type 2 diabetes patients. But payers aren't exactly running to redo their formularies.
Fremont, CA-based Zosano delivered bitter news to its investors on Monday evening, tipping off the market that Eli Lilly had bowed out of their osteoporosis partnership while it had also decided to halt work on a daily dosing program. The news, delivered during a bearish period for biotech stocks, eviscerated its stock, which dropped 43% and reduced its market cap to a mere $42 million.
Eli Lilly and Incyte are now three for three Phase III studies for baricitinib, an oral JAK inhibitor for rheumatoid arthritis that is on track for a marketing application and a real-world test of its lofty blockbuster reputation with analysts--while one already established rival from Pfizer lags well behind expectations.